PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025
PolyPid (Nasdaq: PYPD) said it will report third quarter 2025 financial results and operational highlights before U.S. markets open on Wednesday, November 12, 2025.
The company will host a conference call and webcast at 8:30 AM Eastern Time; registration is recommended at least five minutes before the call. Webcast and dial-in links are provided for live access.
PolyPid noted that following positive Phase 3 results, submission of a New Drug Application (NDA) for D-PLEX100 to prevent abdominal colorectal surgical site infections is expected in early 2026. The company also referenced an oncology, obesity and diabetes pipeline.
PolyPid (Nasdaq: PYPD) ha dichiarato che riferirà i risultati finanziari del terzo trimestre 2025 e i punti salienti operativi prima dell'apertura dei mercati statunitensi mercoledì 12 novembre 2025.
L'azienda terrà una conference call e una webcast alle 8:30 AM ora orientale; si raccomanda di registrarsi almeno cinque minuti prima della chiamata. I link per webcast e per l'accesso telefonico sono forniti per l'accesso in diretta.
PolyPid ha osservato che, a seguito di risultati positivi della fase 3, la presentazione di una New Drug Application (NDA) per D-PLEX100 per prevenire infezioni del sito chirurgico addominale colorectal è prevista all'inizio del 2026. L'azienda ha inoltre menzionato una pipeline oncologica, di obesità e di diabete.
PolyPid (Nasdaq: PYPD) dijo que informará los resultados financieros del tercer trimestre de 2025 y los aspectos operativos antes de la apertura de los mercados de EE. UU. el miércoles 12 de noviembre de 2025.
La compañía organizará una llamada de conferencia y una webcast a las 8:30 AM hora del Este; se recomienda registrarse al menos cinco minutos antes de la llamada. Los enlaces de webcast y de acceso telefónico están disponibles para acceso en vivo.
PolyPid señaló que, tras resultados positivos de la fase 3, se espera la presentación de una Solicitud de Nuevo Fármaco (NDA) para D-PLEX100 para prevenir infecciones del sitio quirúrgico abdominal en colorectal en principios de 2026. La empresa también señaló una cartera oncológica, de obesidad y de diabetes.
PolyPid (Nasdaq: PYPD)가 2025년 3분기 재무 실적과 운영 하이라이트를 미국 시장 개장 전에 2025년 11월 12일 수요일에 발표한다고 밝혔습니다.
회사는 동부 표준시 8:30에 컨퍼런스 콜과 웹캐스트를 주최하며, 콜 시작 최소 5분 전 등록하는 것이 좋습니다. 라이브 접속용 웹캐스트 및 다이얼인 링크가 제공됩니다.
또한 3상 양호 결과에 따라 D-PLEX100에 대한 신약허가신청(NDA)의 제출이 2026년 초에 예상되며, 회사는 종양학, 비만 및 당뇨병 파이프라인도 언급했습니다.
PolyPid (Nasdaq: PYPD) a déclaré qu'il publiera les résultats financiers du troisième trimestre 2025 et les points opérationnels avant l'ouverture des marchés américains le mercredi 12 novembre 2025.
L'entreprise organisera une conférence téléphonique et une webcast à 8:30 AM heure de l'Est; il est recommandé de s'enregistrer au moins cinq minutes avant l'appel. Les liens de webcast et de dial-in sont fournis pour un accès en direct.
PolyPid a noté qu'après des résultats positifs de la phase 3, la soumission d'une Demande de Nouveau Médicament (NDA) pour le D-PLEX100 afin de prévenir les infections du site chirurgical abdominal colorectal est attendue au début 2026. L'entreprise a également fait référence à un portefeuille en oncologie, obésité et diabète.
PolyPid (Nasdaq: PYPD) gab bekannt, dass es die Finanzergebnisse des dritten Quartals 2025 und operative Highlights vor der Öffnung der US-Märkte am Mittwoch, dem 12. November 2025 berichten wird.
Das Unternehmen wird zu 8:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast abhalten; es wird empfohlen, sich mindestens fünf Minuten vor dem Anruf zu registrieren. Webcast- und Dial-in-Links werden für den Live-Zugang bereitgestellt.
PolyPid wies darauf hin, dass nach positiven Phase-3-Ergebnissen die Einreichung eines New Drug Application (NDA) für D-PLEX100 zur Verhinderung von Infektionen am abdominalen kolorektalen Operationsstandort voraussichtlich Anfang 2026 erfolgen wird. Das Unternehmen verwies außerdem auf eine Pipeline in Onkologie, Adipositas und Diabetes.
PolyPid (Nasdaq: PYPD) قالت إنها ستعلن عن النتائج المالية للربع الثالث من عام 2025 ونقاطها التشغيلية قبل افتتاح الأسواق الأمريكية يوم الأربعاء 12 نوفمبر 2025.
ستعقد الشركة مكالمة مؤتمرات وويبكاست في 8:30 صباحاً بتوقيت الساحل الشرقي; يُنصح بالتسجيل قبل خمس دقائق على الأقل من الاتصال. روابط الويبكاست والهاتف متاحة للوصول مباشرة.
أشارت PolyPid إلى أنه عقب نتائج المرحلة الثالثة الإيجابية، من المتوقع تقديم طلب دواء جديد (NDA) لـ D-PLEX100 لمنع عدوى موقع جراحي بالبطن في القولون والمستقيم في بداية 2026. كما أشارت إلى وجود خط أنابيب في الأورام والبدانة والسكري.
PolyPid (纳斯达克：PYPD) 表示将公布 2025 年第三季度 的财务业绩及运营要点，时间为美股开盘前，2025 年 11 月 12 日，星期三。
公司将于 美东时间 8:30 举行电话会议和网络直播；建议在通话前至少五分钟完成注册。将提供网络广播和拨入链接以便实时访问。
PolyPid 指出，在第三阶段结果积极之后，预计在 2026 年初 提交用于预防腹部结直肠外科手术部位感染的 新药申请（NDA）—D-PLEX100。公司还提到在肿瘤学、肥胖和糖尿病方面的管线。
- None.
- None.
Insights
PolyPid schedules Q3 results for
PolyPid will release third quarter 2025 financials and operational highlights before U.S. markets on
Key dependencies include the content of the upcoming financial report and the NDA filing timing and completeness. Risks noted in the release include the usual forward-looking uncertainties and the possibility that management expectations may not materialize. The announcement contains no new financial figures or clinical data beyond the phrase "positive phase 3 results."
Watch the company call on
PETACH TIKVA, Israel, Oct. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 12, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.
Conference Call Dial-In & Webcast Information:
| Date: | Wednesday, November 12, 2025 |
| Time: | 8:30 AM Eastern Time |
| Conference Call: | https://register-conf.media-server.com/register/BIc1123c3d1ebf446fb8b5342dae528d37 |
| Webcast: | https://edge.media-server.com/mmc/p/hgt6udvi |
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. Following positive phase 3 results, New Drug Application (NDA) submission of D-PLEX₁₀₀, PolyPid's lead product candidate, for the prevention of abdominal colorectal surgical site infections, is expected in early 2026. In addition, the Company has an innovative pipeline in oncology, obesity and diabetes.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.
Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing of the NDA submission. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission, including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed on February 26, 2025. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.
References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.
Company Contact:
PolyPid Ltd.
Ori Warshavsky
908-858-5995
IR@Polypid.com
Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
polypid@arxhq.com
FAQ
When will PolyPid (PYPD) report its third quarter 2025 results?
What time is the PolyPid (PYPD) earnings call and webcast on November 12, 2025?
How can investors access PolyPid (PYPD) November 12, 2025 webcast?
What near-term regulatory milestone did PolyPid (PYPD) disclose related to D-PLEX100?
Will PolyPid (PYPD) discuss operational highlights during the November 12, 2025 call?
